EMA Backs Three-Month HIV Prevention Ring

The European Medicines Agency issued a positive scientific opinion for the Population Council's three-month dapivirine vaginal ring for HIV prevention.

Updated on Nov. 16, 2026 in Sexual Health

Isometric editorial illustration of two pale ring forms on a warm ochre surface, one sliced to show layered inner structure, evoking a long-acting HIV prevention device.
The European Medicines Agency issued a positive opinion Tuesday for the Population Council's three-month dapivirine vaginal ring for HIV prevention in women and adolescent girls aged 16 and older. AI Illustration. Upload story photo >

The Population Council announced that the European Medicines Agency has issued a positive scientific opinion for its three-month dapivirine vaginal ring, which supports use for HIV prevention in women and adolescent girls aged 16 and older, including breastfeeding women. The ring slowly releases the antiretroviral drug dapivirine over three months.

Why it matters

The three-month ring is designed to reduce how often users must replace the device, which could lower costs and ease access to HIV prevention. The opinion also lays groundwork for introduction in African markets, where HIV prevention options for women remain a priority.

A Phase I crossover trial of 124 women in South Africa found the three-month ring was well tolerated and delivered higher dapivirine levels than the one-month ring, which Kiara Health will need to confirm in market introductions. The projected annual cost reduction of nearly 60% compared with the unsubsidized one-month ring has not yet been tested at scale.

The players

Population Council

The Population Council is a nonprofit research organization that develops reproductive health and HIV prevention technologies, including the dapivirine vaginal ring.

Kiara Health

Kiara Health is a South Africa-based pharmaceutical manufacturer and healthcare solutions provider that will take over the commercial license for the three-month ring.

The details

The positive opinion followed an evaluation through the EU-Medicines for All procedure. The three-month ring is inserted into the vagina near the cervix and releases dapivirine at the site of potential infection, requiring replacement four times per year. The Population Council will transfer the commercial license to Kiara Health, a South Africa-based pharmaceutical manufacturer.

Timeline

  1. July 2020: The one-month dapivirine ring received a positive EMA scientific opinion.

  2. November 16, 2026: The Population Council announced the EMA positive opinion for the three-month ring.

Health Landscape

This opinion extends the July 2020 positive EMA review of the one-month dapivirine ring, adding a longer-acting option to HIV prevention for women in Africa. It reflects a broader push to develop multi-month delivery methods that reduce how often users must return for replacement.

For women and adolescent girls aged 16 and older, a three-month ring could mean replacing the device four times a year rather than more often. Availability will depend on regulatory approvals and introduction decisions in individual African markets.

The takeaway

A longer-lasting prevention option could ease the burden of frequent replacement for users who depend on HIV prevention. Access will ultimately depend on how quickly the product reaches markets and at what price.

Further reading

Explore more on Sexual Health for context on HIV prevention options and regulatory developments.

More information

Visit the Population Council organization website for information about the dapivirine vaginal ring program.